Introduction
Beta blockers and thiazide diuretics are the most commonly used agents in the treatment of hypertension because of their efficacy and lack of side effects. It is hoped that by lowering blood pressure with these drugs the medium and long-term risk of coronary heart disease is reduced. The Veterans Administration Cooperative Group (1970) provided clear evidence of an effect on cerebrovascular disease morbidity and mortality, but a decrease in cardiac events was not proven. More recently, encouraging evidence of such a reduction in coronary heart disease mortality has been reported by the Hypertension Detection and Follow-up Program Cooperative Group (1979a, b) . However, the authors considered that the data for cause of death were too unreliable to permit conclusions to be drawn. It therefore seems that therapy of hypertension is more effective in reducing cerebrovascular disease than coronary heart disease.
Since it is known that plasma lipoprotein concentrations are more strongly associated with coronary heart disease than cerebrovascular disease (Ballantyne et al., 1974) , it is possible that agents which adversely affect plasma lipoproteins may have a greater influence in reducing benefit in coronary heart disease than in cerebrovascular disease. With the exception of free fatty acids, lipids are transported in plasma complexed with specific apoproteins as lipoproteins. There are 4 major classes of lipoproteins: chylomicrons, very low density lipoproteins (VLDL), low density lipoproteins (LDL) and high density lipoproteins (HDL) . Chylomicrons are rarely present in fasting serum and will not be discussed. Epidemiological studies have indicated that elevated LDL and reduced HDL concentrations are associated with an increased risk of coronary heart disease (Kannel, Castelli and Gordon, 1979; Heiss et al., 1980) . It is therefore important to examine the effects of drugs commonly used in the treatment of hypertension on these lipoproteins.
The purpose of this paper is to review present knowledge concerning the relationship between betablockers, thiazide diuretics and lipoprotein concentrations.
Thiazide diuretics and lipoproteins Schoenfield and Goldberger (1964) reported that thiazide diuretics adversely affected serum cholesterol concentrations, but their study was not followed up for about a decade. Some of the more recent studies are shown in Table 1 . Ames and Hill (1976a, b) showed that 6 months' treatment with the thiaziderelated diuretic chlorthalidone, which, like thiazide diuretics, acts on the distal tubule, was associated with a rise in plasma triglyceride and cholesterol. Interpretation of their findings was complicated by the prescription of a salt-restricted diet to all patients. Twenty-five of the 32 patients in the chlorthalidonetreated group received a calorie-restricted diet and 27 received a lipid-lowering diet. A number of other studies have been published concerning the effect of up to 6 months therapy on plasma lipids. Grimm et al. (1981) confirmed the elevation in plasma triglycerides and cholesterol but Gluck et al. (1980 ), Bauer et al. (1981 ) and Meier et al. (1982 found no significant changes. In one report, 6 weeks treatment with chlorthalidone produced a rise in VLDL-and LDLcholesterol, whereas with hydrochlorothiazide, only VLDL-cholesterol was increased (Grimm et al., 1981) . The rise in LDL-cholesterol has been confirmed in other investigations of short-term therapy with thiazide diuretics (Gluck et al., 1980); Meier et al., 1982) , but no rise in VLDL was observed and, in the study of Gluck et al. (1980) , there was a fall in Avogaro et al. (1979) concluded that apoAl and apoB concentrations may be as effective discriminators for risk of coronary heart disease as total cholesterol and triglyceride concentrations in subjects less than 50 years old and to be better discriminators in older subjects. Gluck et al. (1980) measured apoB and apoAl in their study of chlorthalidone. Despite a rise in LDL-cholesterol, no change in apoB was found and the authors suggested that this indicated that the LDL particle had become enriched in cholesterol but that the number of LDL particles had not increased. The authors speculated that this effect on LDL might be mediated through an effect on the liver. ApoAI was also not significantly altered despite a fall in HDL-cholesterol concentration. The authors did not suggest an explanation for this discrepancy. There are also conflicting results of the effect of long-term therapy, i.e. for greater than 6 months. Two reports of the effect of hydrochlorothiazide after 4 years (Helgeland, Hjermann and Leren, 1978a) and after 3 years (Helgeland et al., 1978b) showed no significant change in plasma triglyceride, total cholesterol or HDL-cholesterol. More recently, Goldman et al. (1980) reported that when chlorthalidone was given to 610 patients with mild hypertension for 1 year, there were significant increases in plasma total triglyceride and cholesterol concentrations, together with a significant elevation of LDL-cholesterol. No change in HDL was found and results for VLDL were not presented.
There is no obvious explanation for the discrepancies in the results of the above studies. Compliance has rarely been assessed and may be a problem particularly in long-term studies. It is likely that there may have been differences in the quality assurance programmes operated by the participating laboratories.
In summary, no firm conclusions can be drawn as to the effect of long-term therapy with hydrochlorothiazide or chlorthalidone on plasma lipids or lipoproteins. Treatment probably does cause an acute change in the lipoprotein profile. The most consistent changes are increases in plasma total triglyceride and cholesterol concentrations together with an increase in LDL-cholesterol. Since only one report found a significant fall in HDL-cholesterol (Gluck et al., 1980) , it is unlikely that thiazide diuretics significantly affect this lipoprotein.
Both hydrochlorothiazide and chlorthalidone promote sodium and water excretion. Their principal sites of action are the upper part of the ascending limb of the loop of Henle and the beginning of the distal tubule. The mechanism by which these drugs alter the lipoprotein concentrations is not clear. Lipoproteins are not found normally in tubular fluid, because they are too large to be filtered by the normal glomerulus. Even when the glomerular membrane suffers extensive damage as in the nephrotic syndrome, only HDL escapes into the filtrate. We are aware of no evidence of effects of either hydrochlorothiazide or chlorthalidone on lipoprotein metabolism in, for example, liver or gut. The age of the patient was not considered to be a factor (Goldman et al., 1980) . Haematocrit and albumin changes have been reported to be small and insufficient to explain the short-term changes in lipoproteins (Grimm et al., 1981) . However, one study of the effect of 6-24 months' therapy with thiazides reported persistent plasma volume contraction (Tarazi, Dustan and Frohlich, 1970) . Thus, it is possible that, changes in plasma volume may be important in long-term studies. It is interesting, but unexplained that in one report (Goldman et al., 1980) , there was an inverse relationship between the change in plasma cholesterol and the baseline cholesterol concentration.
Apart from the study of Gluck et al. (1980) , in which apoB and apoAl were estimated, there is little evidence on the effects of thiazide diuretics on apolipoproteins or on HDL subfractions. HDL2 has been shown to be significantly reduced in patients with established coronary heart disease whereas no change was found in HDL3 (Ballantyne et al., 1982) . It is possible that an alteration in the proportion of these 2 subfractions, which may influence risk of atherosclerosis, could be induced by therapy with or without a significant alteration in total HDL-cholesterol. Further research on these aspects is required.
Beta-adrenoceptor blocking agents and lipoproteins
A summary of papers published in the last decade is given in Table 2 . Eight subjects with elevated fasting plasma triglyceride levels, who received a 60 g fat meal before and after 3 weeks treatment with propranolol showed an enhanced lipaemic response to the meal after the therapy (Barboriak and Friedberg, 1973) . The data also suggested a small, but not statistically significant, increase in fasting plasma triglyceride levels after only a 2-week exposure to the drug. This rise in plasma triglyceride was not confirmed by Tanaka et al. (1976) who gave propranolol for 8 weeks to 10 patients who had suffered cerebrovascular accidents. However, despite the lack of a significant change in total triglyceride, there was a significant rise in VLDL-triglyceride, which was accompanied by falls in LDL-triglyceride and in HDL-cholesterol concentrations. Post-heparin lipolytic activity was significantly suppressed by propranolol and the authors considered that inhibition of lipoprotein lipase by propranolol might have played a role in the reciprocal changes in lipoprotein lipids.
There have been 4 more recent studies of the effect of propranolol therapy (see Table 2 ). The duration of treatment ranged from 4 (Bauer et al., 1981) to 24 weeks (Day et al., 1979) . In one study, however, the length of treatment was not reported (Streja and Mynin, 1978) . Two of the four studies (Day et al., 1979; Leren et al., 1980) reported a significant increase in plasma triglyceride, and none showed a significant change in plasma total cholesterol. In 3 of these studies, HDL-cholesterol was analyzed (Streja and Mynin, 1978; Leren et al., 1980; Bauer et al., 1981) but in only 2 were significant falls in HDL recorded (Streja and Mynin, 1978; Leren et al., 1980) . In contrast to the report by Tanaka et al. (1976) , VLDL and LDL concentrations were unchanged in the studies of Leren et al. (1980) It has been shown that, in adipose tissue, the lipid mobilizing effect of catecholamines is mediated through stimulation of the beta-adrenergic receptors (Smith, 1980) Most studies to date have been performed on readily accessible blood cells and adipocytes (Motulsky and Insel, 1982) .
The cardioselective agents atenolol and metoprolol have been extensively studied. Four reports concerning metoprolol and 3 of atenolol have been reviewed (Table 2) . Only the study of Eliasson, Lins and Rossner (1981) lasted for longer than 6 months. Three groups reported an increase in plasma triglyceride (Waal-Manning, 1976; Day et al., 1979; England et al., 1980) , but 4 found no significant change (Nilsson, Hannson and Hokfelt, 1977; Beinart et al., 1979; England et al., 1980; Eliasson et al., 1981) .
In none of these studies was a rise in plasma total cholesterol found. England et al. (1980) , who investi-gated both metoprolol and atenolol over 12 weeks, found that they produced a fall in HDL-cholesterol, whereas Eliasson et al. (1981) found no change in this lipoprotein after 32 weeks of atenolol therapy. The latter authors, however, reported increased VLDLand LDL-triglyceride concentrations.
The presence of cardioselectivity therefore does not appear to produce more consistent changes than those found with non-selective beta blockers. Where significant changes were found they were similar to those reported with non-selective agents, i.e., a rise in plasma triglyceride and a fall in HDL-cholesterol. As with non-selective drugs, there is a paucity of longterm studies, only one being conducted for more than 6 months (Eliasson et aL, 1981) . There is an obvious need for more such investigations.
A further property of some beta-adrenoceptor blocking agents, which might influence the effect on plasma lipoproteins, is the presence of ISA. Oxprenolol has ISA, but pindolol has significantly greater ISA. In a 3-week investigation of oxprenolol, Sommers et al. (1981) reported a significant decrease in plasma total cholesterol with no change in plasma triglyceride or HDL (VLDL and LDL concentrations were not measured). In contrast, Ballantyne, Ballantyne and McMurdo (1981) found significant rises in plasma total and LDL-cholesterol after 16 weeks of therapy. No change was found in plasma triglyceride, VLDL-cholesterol or HDL-cholesterol. The explanation for this discrepancy may lie in differences in the duration of the studies and in differences in lipoprotein methodology and possibly in quality assurance. It has recently been suggested by Lehtonen et al. (1982) in a 26-week study that pindolol significantly lowers plasma total cholesterol and raises HDLcholesterol. However, the rise in HDL was only significant at 1 month. These effects of pindolol require confirmation. In summary, therefore, the literature concerning the effect of beta-adrenoceptor blocking agents on plasma lipoproteins is conflicting. No consistent differences arise from the presence of cardioselectivity or ISA. In this regard, it is relevant that the one study involving the cardioselective drug practolol which also possesses ISA (Ghosh, Cochrane and de Bono, 1975) , showed no significant changes in plasma lipids following 12 months treatment. There are few studies lasting more than 6 months and since these drugs are usually prescribed on a long-term basis, further investigations are obviously required.
Combined therapy with beta-adrenoceptor blocking drugs and thiazide diuretics
Results from 5 recent studies are presented in Table 3 . Four of the investigations use a thiazide diuretic and propranolol. A significant increase in plasma triglyceride without alteration in plasma cholesterol was found by Helgeland et al. (1978a) , England, Hua and Shaw (1978) and Bauer et al. (1981) . In one study, a significant fall in HDLcholesterol was found (Helgeland et al., 1978a) but in 2 this lipoprotein was unchanged (Kristenson, 1981; Bauer et al., 1981) . Only in one were VLDL and LDL analyzed (Bauer et al., 1981) and a rise in VLDLtriglyceride concentration was found. The results of this latter trial were similar to those reported by Ballantyne et al. (1981) who investigated combined therapy with slow oxprenolol and cyclopenthiazide but contrast with the report by Crisp et aL (1980) who found no increase in total triglyceride on this combined therapy. England et al. (1978) also reported increases in plasma triglyceride following 4 weeks therapy with chlorothiazide and atenolol or pindolol or metoprolol.
Unlike the literature dealing with monotherapy with either thiazides or beta-adrenoceptor blocking drugs, reports on combined therapy are reasonably consistent. The main effect is a rise in plasma triglyceride with only one study reporting a fall in HDL-cholesterol. This is rather surprising in view of the known reciprocal relationship between plasma triglyceride and HDL-cholesterol concentrations (Ballantyne, Olsson and Carlson 1978a, b) .
Summary
Some of the more important recent studies on the effect of thiazides and beta-adrenoceptor blocking agents on plasma lipoproteins have been reviewed. The evidence for an effect of monotherapy with either thiazide or beta-adrenoceptor blocking agents is conflicting, possibly because of differences in patient compliance and in lipoprotein methodology and quality assurance between studies. It is likely that in the short-term, thiazide diuretics produce an increase in plasma triglyceride and cholesterol and in LDL-cholesterol. No consistent effect of monotherapy with beta-adrenoceptor blocking agents was seen. Further long-term studies of monotherapy with both of these classes of drugs are required. Combined therapy with thiazides or beta-adrenoceptor blocking agents consistently increased plasma triglyceride concentrations, but their effect on VLDL, LDL and HDL concentrations is uncertain. Further T search is required into the effect of these drugs on apolipoproteins which may be useful discriminators for patients with coronary heart disease (Avogaro et al., 1979) and on HDL subfractions. 
